Page 200 - Haematologica May 2022

Letters to the Editor
Pennsylvania, Philadelphia, PA and 14Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
Correspondence:
ERIN GUEST - eguest@cmh.edu doi:10.3324/haematol.2021.280146 Received: October 4, 2021. Accepted: February 4, 2022. Pre-published: February 17, 2022.
Disclosures: the authors declare no competing financial interests in relation to the work described. EMG received consulting fees from Syndax and is a member of a Speakers Bureau for Jazz. LG provides unpaid Scientific Advisory Board service to Amgen, Janssen, Kura, OnKure, Pfizer, and Syndax, and owns common stock in Amgen, Deciphera, ITOS, Mirati, and Sanofi Paris. EAR received research funding from Pfizer (institutional) and serves on a DSMB for Celgene. SPH received consulting fees from Novartis, honoraria from Amgen, Jazz, and Servier, and owns common stock in Amgen.
Contributions: the study was designed by EMG, JAK, MLL, SPH, and PAB; the statistical design and analyses were performed by JAK, CYW, and MD; the cytogenetics data was provided by AJC and NAH; EMG wrote the manuscript, with contributions from all authors. All authors gave final approval of the manuscript.
Acknowledgments: LG is the Ergen Family Chair in Pediatric Oncology at Children’s Hospital Colorado. MLL is the Benioff Chair of Children’s Health and the Deborah and Arthur Ablin Endowed Chair for Pediatric Molecular Oncology at Benioff Children’s Hospital. EAR is a KiDS of NYU Foundation Professor at NYU Langone Health. SPH is the Jeffrey E. Perelman Distinguished Chair in Pediatrics at The Children’s Hospital of Philadelphia.
Funding: this study was supported by NIH grants U10 CA98543 (COG Chair’s Grant), U10 CA180886 (NCTN Operations Center Grant), U10 CA98413 and U10 CA180899 (COG Statistics and Data Center Grants), and St. Baldrick’s Foundation.
Data sharing statement: requests for access to COG protocol research data should be sent to: datarequest@childrensoncologygroup.org
Disclaimer: the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References
1. Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer. 2015;62(3):419-426.
2. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III random- ized study. J Clin Oncol. 2019;37(25):2246-2256.
3. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250.
4. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441- 451.
5. Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified thera- py for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
6. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007;21(11):2258-2263.
7. Nagayama J, Tomizawa D, Koh K, et al. Infants with acute lym- phoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood. 2006;107(12):4663-4665.
8. Brown PA, Kairalla JA, Hilden JM, et al. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021;35(5):1279-1290.
9. Salzer WL, Jones TL, Devidas M, et al. Decreased induction morbid- ity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(3):414-418.
10.Kaplan E, Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Peto R, Pike MC, Armitage P, et al. Design and analysis of random- ized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1-39.
12. Fazio G, Bardini M, De Lorenzo P, et al. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. Blood. 2021;137(14):1980-1984.
13. Boer JM, Valsecchi MG, Hormann FM, et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lym- phoblastic leukemia in a collaborative international study. Leukemia. 2021;35(10):2978-2982.
14. De Lorenzo P, Moorman AV, Pieters R, et al. Cytogenetics and out- come of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia. 2014;28(2):428-430.
1208
haematologica | 2022; 107(5)